Compare BJ & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BJ | ABVX |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Department/Specialty Retail Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 10.5B |
| IPO Year | 2018 | N/A |
| Metric | BJ | ABVX |
|---|---|---|
| Price | $96.70 | $109.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 12 |
| Target Price | $109.40 | ★ $128.42 |
| AVG Volume (30 Days) | ★ 1.7M | 714.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.09 | N/A |
| EPS | ★ 3.42 | N/A |
| Revenue | ★ $20,501,804,000.00 | N/A |
| Revenue This Year | $9.10 | N/A |
| Revenue Next Year | $6.71 | $0.22 |
| P/E Ratio | $28.83 | ★ N/A |
| Revenue Growth | ★ 2.67 | N/A |
| 52 Week Low | $86.68 | $4.77 |
| 52 Week High | $121.10 | $148.83 |
| Indicator | BJ | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 38.48 |
| Support Level | $95.12 | $107.99 |
| Resistance Level | $99.52 | $131.27 |
| Average True Range (ATR) | 3.47 | 5.11 |
| MACD | -0.32 | -1.73 |
| Stochastic Oscillator | 36.11 | 14.40 |
BJ's Wholesale Club, founded in 1984, operates a membership-based warehouse club model primarily along the US East Coast, with roughly 250 clubs and a growing domestic presence across 21 states. In fiscal 2024, the company generated over $20 billion in revenue. BJ's offers a value-oriented assortment skewed toward grocery, perishables, and consumables (71% of sales), general merchandise (11%), and gasoline (18%). Its business model is supported by recurring membership fee income and private-label brands such as Wellsley Farms and Berkley Jensen.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.